'Fiery' Cell Death During Chemotherapy May Drive Bladder Cancer Resistance
New research suggests that chemotherapy-induced inflammatory cell death may promote bladder cancer resistance by activating support cells, highlighting potential for targeted combination therapies to improve outcomes.
Recent research from Houston Methodist reveals that the inflammatory response triggered by chemotherapy, specifically a form of cell death called pyroptosis or 'fiery death,' may inadvertently contribute to bladder cancer's resistance to treatment. Traditionally, chemotherapy aims to eliminate cancer cells; however, this study demonstrates that the process of pyroptosis can activate support cells within the tumor, known as fibroblasts, causing them to produce collagen. This collagen provides a protective environment for cancer stem cells, enabling them to survive treatment and potentially leading to recurrence.
The investigation, detailed in the publication "Caspase-1–dependent pyroptosis converts αSMA+CAFs into collagen-III high iCAFs to fuel chemoresistant cancer stem cells" in Science Advances, utilized mouse models and patient samples for analysis. The researchers found that blocking this inflammatory pathway with the drug belnacasan could reduce collagen production, thereby improving the effectiveness of chemotherapy.
Notably, not all forms of cell death are beneficial in cancer treatment. The study emphasizes that the inflammatory type of cell death associated with pyroptosis may promote tumor survival instead of eradication. Dr. Hongbo Gao and Dr. Keith Syson Chan explained that this inflammatory response creates a microenvironment conducive to cancer stem cell survival, fueling resistance.
Therapeutically, combining standard chemotherapy with inhibitors like belnacasan holds promise for overcoming resistance in bladder cancer. The research suggests that targeting the inflammatory processes initiated during pyroptosis could enhance treatment outcomes. While further studies are needed across different tumor types, initial evidence indicates similar strategies might benefit other cancers, including breast cancer.
This discovery underscores the complexity of cancer biology and highlights the importance of understanding immune responses during cancer therapy. Modulating these reactions could lead to more effective treatment protocols and reduce recurrence rates in bladder cancer patients.
Source: https://medicalxpress.com/news/2025-07-fiery-cell-death-chemotherapy-bladder.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Repositioning Rheumatoid Arthritis Medication to Combat COVID-19-Induced Inflammation
A promising study reveals that iguratimod, a drug used for rheumatoid arthritis, may help reduce excessive inflammation in COVID-19 patients without compromising immune response. This could lead to safer therapies for managing severe COVID-19 complications.
Rectal Bleeding in Young Adults Significantly Raises Risk of Colorectal Cancer
Rectal bleeding in young adults significantly increases the risk of colorectal cancer, with affected individuals being 8.5 times more likely to be diagnosed. This highlights the importance of prompt investigation and reevaluation of screening guidelines for younger populations.
Semaglutide Shows Promise in Improving Metabolic and Physical Health in Patients with Schizophrenia on Antipsychotics
A recent Danish study finds that weekly semaglutide improves blood sugar, promotes weight loss, and enhances physical health in adults with schizophrenia on antipsychotics, highlighting its potential as a safe and effective treatment option.
Newly Identified Molecule May Clarify Muscle Loss in Type 2 Diabetes
Scientists have discovered a new molecule, TMEM9B-AS1, that may explain muscle loss in people with type 2 diabetes, offering potential for targeted treatments.